Reported 1 day ago
Pfizer is fully committed to developing its experimental obesity drug, danuglipron, as CEO Albert Bourla announced plans to recruit more experts in this field during the JPMorgan Healthcare Conference. The company aims to initiate late-stage studies by the second half of the year and is focusing on a once-a-day pill that could offer a convenient alternative to existing injectable treatments. Bourla expressed cautious optimism about the drug's competitive potential in the rapidly growing weight-loss market.
Source: YAHOO